Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2012

View Archived Issues

Promising data disclosed on apremilast in psoriasis and atopic dermatitis

UCB provides pipeline progress report for 2011

U.S. study reveals new prognostic marker of aggressive kidney cancer

New PET imaging agents designed at Bayer Schering Pharma

University of California, Oakland divulges novel diagnostics

New boron-based ROCK inhibitors show potential to treat inflammation and hypertension

GenVec receives NIAID grant for vaccine program

ScinoPharm and NHRI to begin phase I trial of DBPR-108

FDA approves dry nasal aerosol product for allergic rhinitis

Merck & Co. selects new agent for development in diabetes

EMA accepts lorcaserin MAA for review

Clavis Pharma provides update relating to phase III CLAVELA trial

First descriptions provided of BMS products now in phase II testing

Celtic Therapeutics launches new company

Nippon Shinyaku seeks approval of drug for persons with alcohol dependence

New antibodies designed to treat and prevent influenza

New candidate cancer therapies presented

Novel IL-18R1-binding antibodies presented by Roche

Neurocrine Biosciences reports on phase II study in tardive dyskinesia

Astellas Pharma files MAA for new fixed-dose combination tablet for LUTS

CSL Behring kicks off enrollment in PATH trial

Cell Therapeutics gives update on Opaxio study in GBM

FDA issues complete response letter for Levadex NDA

Medgenics receives recommendations from NIH committee for phase II trial

Insys Therapeutics launches fentanyl sublingual spray in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...